Company and Stock Identity

How Sanofi Connects to the Public Market

Company structure
Public company
Market access
Direct listing: Nasdaq: SNY. The ordinary shares are listed on Euronext Paris, and the Nasdaq listing is an ADR programme.
Stock name
Sanofi
Ticker and exchange
Nasdaq: SNY
Research focus
Sanofi calls itself AI-powered on its own about page, which makes it worth separating the software it licenses from the software it built. When an AI company announces a Sanofi agreement, check the term and whether it covers one research group or the whole pipeline, because a multi-year licence with no disclosed value can still be a narrow pilot. The pipeline figures of 61 compounds and 20 phase 3 trials come from the company's own page and change often.

Sanofi is publicly held with no controlling owner. Its own investor pages say the ordinary shares are listed on Euronext Paris and are also available on the Nasdaq under the symbol SNY, give the ADR to ordinary share ratio as 1:2, and name J.P. Morgan Chase Bank as the depositary bank. Verified on the company's own investor pages on October 24, 2026.

Dated Market Snapshot

Oct 26, 2026

Last price
$41.79
Change
+0.46%
Previous close
$41.60
52-week high / low
$52.68/$39.07
Market cap
101,919,716,684

Automated from Nasdaq. Check the exchange or investor-relations page for the current price.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Owkin ... Company source

Sanofi signs a five-year licence for Owkin's K Pro and asks for AI agents built for its own teams

Owkin announced on 5 June 2026 a five-year licence with Sanofi for K Pro, the product Owkin calls its AI Scientist, together with work to build what it describes as next-generation biopharma agents purpose-built for Sanofi. Owkin says the agents are meant to act as assistants that carry out complex tasks in drug research and development on their own, across the span from early discovery through clinical development, and to support competitive intelligence and decision-making. The announcement discloses no financial terms. Thomas Clozel, Owkin's co-founder and chief executive, is quoted saying that building on the existing collaboration with Sanofi marks a shift toward truly embedded AI. Emmanuel Frenehard, Sanofi's chief digital officer, is quoted saying that putting purpose-built agentic systems into the company's workflows is meant to let its teams work with greater speed, depth and confidence.

Why it matters: The length is the signal. A five-year licence has to survive budget reviews and a change of leadership, which a one-year pilot does not, so Sanofi has committed to living with this software rather than testing it. Two things are worth holding at arm's length. No money was disclosed, so the term tells you about intent and not about scale. And the word autonomous is doing a lot of work: an agent that writes a research summary without being asked is useful, while an agent that prioritises which molecule to pursue is a decision, and the announcement does not separate the two. Note also that Sanofi's chief digital officer is the named executive rather than a research leader, which suggests this started as a digital programme.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Sanofi's careers site lists its openings under research and development, digital, a digital accelerator, manufacturing and supply, engineering and maintenance, quality, regulatory affairs, medical and market access, marketing and sales, corporate functions and business operations, and hubs, plus apprenticeships, internships and graduate programmes.

Qualification signal: The digital and digital accelerator areas are the ones to watch for AI work, and they sit apart from research and development on the company's own careers site. That split matters: someone who wants to work on drug discovery AI should look at which of the two owns the project, because a digital team role and a research role at the same company can involve very different science.

Check current roles at Sanofi. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Research and development leaders, clinical development teams, business development staff, and investors tracking where AI partnerships lead
Primary use case
Sponsor, license, or partner on AI research, molecule design, and trial measurement in drug development
Typical deployment
Drug developer. AI arrives through a research collaboration, a licence, or a tool used inside a clinical trial.

Evidence questions

  • What stage did the agreement reach, and were any payments or milestones disclosed?
  • Which programs or molecules does the AI work actually touch?
  • Has anything from the collaboration reached a clinical endpoint rather than a press release?

Regulatory and workflow questions

  • If AI produced a measurement used in a trial, has a regulator accepted that measurement?
  • Which regulatory submissions, if any, depend on the AI work?
  • Who is responsible for the quality of an AI-generated result inside a trial record?

Data and contract questions

  • Whose data trained the model, and what did the drug company contribute?
  • Who owns a molecule or design the collaboration produces?
  • What happens to the shared data if the collaboration ends?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources